Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

Autor: Meulendijks, Didier, Lassen, Ulrik N, Siu, Lillian L, Huitema, Alwin D R, Karanikas, Vaios, Mau-Sorensen, Morten, Jonker, Derek J, Hansen, Aaron R, Simcox, Mary E, Schostack, Kathleen J, Bottino, Dean, Zhong, Hua, Roessler, Markus, Vega-Harring, Suzana M, Jarutat, Tiantom, Geho, David, Wang, Karen, DeMario, Mark, Goss, Glenwood D, Schellens, Jan H M

PURPOSE: The TWEAK-Fn14 pathway represents a novel anticancer target that is being actively investigated. Understanding the relationship between pharmacokinetics of anti-TWEAK therapeutics and tumor pharmacodynamics is critical. We investigated expos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______101::ccea9021daede2614056a1b34b81dfe6
https://dspace.library.uu.nl/handle/1874/346853

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

Autor: Meulendijks D; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lassen UN; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark., Siu LL; Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Huitema AD; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Karanikas V; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Zurich, Switzerland., Mau-Sorensen M; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark., Jonker DJ; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada., Hansen AR; Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Simcox ME; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Schostack KJ; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Bottino D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Zhong H; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Roessler M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany., Vega-Harring SM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany., Jarutat T; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany., Geho D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Wang K; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., DeMario M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York., Goss GD; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada., Schellens JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, the Netherlands. j.schellens@nki.nl.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Feb 15; Vol. 22 (4), pp. 858-67. Date of Electronic Publication: 2015 Oct 07.